Grants and Contributions

About this information

In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.

The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.

Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.

Grants and Contributions Dataset
Found 508 records

Not-for-profit organization or charity

Agreement:

Aide d’urgence en santé – Appui à la réponse au choléra – Haïti - 2022

Number:

7446075 P012320001

Duration: from Dec 23, 2022 to Aug 31, 2023
Description:

Project activities include: (1) strengthening epidemiological surveillance; (2) supporting early and appropriate case management; (3) training health community workers; and (4) providing medical supplies and vaccinations as appropriate.

Organization: Global Affairs Canada
Program Name: International Development Assistance Program
Location: Washington, zz, US

$57,000,000.00

Dec 5, 2022

Not-for-profit organization or charity

Agreement:

COVID-19 Vaccine Delivery and Demand

Number:

7444487 P011860001 P011860002

Duration: from Dec 5, 2022 to Dec 31, 2024
Description:

This Project aims to reduce the incidence of COVID-19 related death and serious illness, particularly amongst priority groups and vulnerable populations, by increasing equitable access to and uptake of COVID-19 vaccines in five countries in the African region. The Project will support health systems strengthening to enable the delivery of gender-equitable COVID-19 vaccination and routine health services.

Organization: Global Affairs Canada
Program Name: International Development Assistance Program
Location: Geneva, zz, CH

Not-for-profit organization or charity

Agreement:

Global Famine Response - FAO – 2022/2023

Number:

7444560 P012093001

Duration: from Oct 31, 2022 to Dec 31, 2023
Description:

Examples of livelihood-based anticipatory actions for agriculture include: (1) rehabilitating water harvesting systems and reinforcing river banks; (2) distributing conditional or unconditional cash transfers, crop varieties, animal feed and supplements; (3) protecting livestock including vaccination, animal health campaigns and evacuation; and (4) diversifying livelihood.

Organization: Global Affairs Canada
Program Name: International Development Assistance Program
Location: Rome, zz, IT

$2,000,000.00

Oct 1, 2022

Individual or sole proprietorship

Agreement:

Team Grant: Monkeypox Rapid Research Response

Number:

168305

Duration: from Oct 1, 2022 to Sep 30, 2023
Description:

To be eligible to the competition, applications must be co-led by Canadian and African researchers and address all objectives:

• Provide rapid evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and across jurisdictions in Canada and internationally;
• Undertake robust, multi-country cross learning, and comparative research (including in collaboration with other international researchers where appropriate) on:
o the safety and real-world effectiveness of medical or other countermeasures deployed* (including vaccines and therapeutics) to treat and/or prevent monkeypox infections in people in Canada and globally; and
o the underlying serological histories and transmission dynamics of the current monkeypox outbreaks in Canada and globally (including time of exposure and transmission during asymptomatic phase, mechanisms of human-to-human transmission, and key risk factors for infection and transmission);
• Align with and contribute to the WHO Global Clinical Platform for monkeypox and other international monkeypox surveillance and research coordination activities by:
o adopting WHO case investigation and reporting forms;
o developing robust study protocols that can be integrated and harmonized with international clinical datasets; and
o contributing to global real-time sharing and analyses of research findings across different study contexts
*Please note that medical countermeasures against monkeypox (including vaccines, drugs and other therapeutic agents) will not be provided by the Government of Canada for research supported through this funding opportunity.

Organization: Canadian Institutes of Health Research
Program Name: Research in Priority Areas
Location: Toronto, ON, CA M5B 1W8

$1,840,500.00

Oct 1, 2022

Individual or sole proprietorship

Agreement:

Team Grant: Monkeypox Rapid Research Response

Number:

168306

Duration: from Oct 1, 2022 to Sep 30, 2023
Description:

To be eligible to the competition, applications must be co-led by Canadian and African researchers and address all objectives:

• Provide rapid evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and across jurisdictions in Canada and internationally;
• Undertake robust, multi-country cross learning, and comparative research (including in collaboration with other international researchers where appropriate) on:
o the safety and real-world effectiveness of medical or other countermeasures deployed* (including vaccines and therapeutics) to treat and/or prevent monkeypox infections in people in Canada and globally; and
o the underlying serological histories and transmission dynamics of the current monkeypox outbreaks in Canada and globally (including time of exposure and transmission during asymptomatic phase, mechanisms of human-to-human transmission, and key risk factors for infection and transmission);
• Align with and contribute to the WHO Global Clinical Platform for monkeypox and other international monkeypox surveillance and research coordination activities by:
o adopting WHO case investigation and reporting forms;
o developing robust study protocols that can be integrated and harmonized with international clinical datasets; and
o contributing to global real-time sharing and analyses of research findings across different study contexts
*Please note that medical countermeasures against monkeypox (including vaccines, drugs and other therapeutic agents) will not be provided by the Government of Canada for research supported through this funding opportunity.

Organization: Canadian Institutes of Health Research
Program Name: Research in Priority Areas
Location: Winnipeg, MB, CA R3T 2N2

$75,000.00

Sep 19, 2022

For-profit organization

Agreement:

ARP – Feasibility – Development of a solution against avian flu.

Number:

995144

Duration: from Sep 19, 2022 to Oct 31, 2023
Description:

Development of a vaccine against avian flu.

Organization: National Research Council Canada
Program Name: Industrial Research Assistance Program – Contributions to Firms
Location: Levis, QC, CA G6W 0L9

$6,659,050.00

Sep 1, 2022

For-profit organization

Agreement:

COVID-19 Rapid Response: Assessment of the Effect of lung-directed Site-Specific Immunomodulator (SSI) in clinical trial QBKPN-CV-01: Assessment of the Effect of QBKPN Site-Specific Immunomodulator (SSI) on Innate Immunity and COVID-19 Vaccine Immune Response and Maintenance in Adults 65 Years of Age or Older

Number:

995430

Duration: from Sep 1, 2022 to Mar 31, 2024
Description:

This project will support a Phase 2, randomized, placebo-controlled clinical trial designed to test the effectiveness of a lung-directed immunomodulator on immune response, restoration of innate immunity and/or reduction of morbidity and mortality from COVID-19 in a test population of adults 65 years of age or older in long term care or assisted living facilities.

Organization: National Research Council Canada
Program Name: Industrial Research Assistance Program – Contributions to Firms
Location: Burnaby, BC, CA V5G 4X4

$10,000,000.00

Sep 1, 2022

For-profit organization

Agreement:

Providence COVID-19 Vaccine Development - STAGE 3

Number:

998413

Duration: from Sep 1, 2022 to Mar 15, 2023
Description:

Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in mid-2023 and pursue market or emergency approvals to commercialize in late 2023 or early 2024. The objective of this project is to facilitate the company's R&D efforts and vaccine development program to begin a Phase 3 clinical trial in 2023.

Organization: National Research Council Canada
Program Name: Industrial Research Assistance Program – Contributions to Firms
Location: Calgary, AB, CA T2Z 3P2

$102,000.00

Sep 1, 2022

For-profit organization

Agreement:

Elarex Viral Vectored Exosomal Vaccine Development and Stabilization

Number:

998641

Duration: from Sep 1, 2022 to Mar 31, 2023
Description:

Optimization of ultra-stable formulation for viral vectored vaccine, compatible with oral dosing

Organization: National Research Council Canada
Program Name: Industrial Research Assistance Program – Contributions to Firms
Location: Burlington, ON, CA L7L 4X5

$408,052.43

Jul 25, 2022

Not-for-profit organization or charity

Agreement:

Canada's assessed contribution to the World Customs Organization

Number:

7442105 P005333001

Duration: from Jul 25, 2022 to Mar 31, 2023
Description:

The World Customs Organization (WCO) is an independent intergovernmental body whose mission is to enhance the effectiveness and efficiency of customs administrations. The WCO currently has 177 member governments. A member of the WCO, Canada has taken a key role in areas such as trade facilitation, revisions to the Harmonized System, capacity building, combating counterfeiting and the development and implementation of the Framework of Standards to Secure and Facilitate Global Trade (SAFE). Canada’s contribution to the WCO advances its interests internationally, particularly given the importance of international trade for the Canadian economy.

Organization: Global Affairs Canada
Program Name: ## PROGRAM INFO N/A ##
Location: Brussels, zz, BE
Date modified: